BioCryst Pharmaceuticals
(NASDAQ) BCRX
BioCryst Pharmaceuticals Financials at a Glance
Market Cap
$2.42B
Revenue (TTM)
$874.84M
Net Income (TTM)
$263.86M
EPS (TTM)
$1.20
P/E Ratio
8.03
Dividend
$0.00
Beta (Volatility)
1.12 (Average)
Dividend
$0.00
Beta (Volatility)
1.12 (Average)
Price
$9.40
Volume
263,774
Open
$9.88
Price
$9.40
Volume
263,774
Open
$9.88
Previous Close
$9.40
Daily Range
$9.25 - $10.11
52-Week Range
$6.00 - $11.31
Dividend
$0.00
Beta (Volatility)
1.12 (Average)
Price
$9.40
Volume
263,774
Open
$9.88
Previous Close
$9.40
Daily Range
$9.25 - $10.11
52-Week Range
$6.00 - $11.31
BCRX News
BCRX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout BioCryst Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
435
CEO
Jon P. Stonehouse
Website
www.biocryst.comHeadquarters
Durham, NC 27703, US
BCRX Financials
Key Financial Metrics (TTM)
Gross Margin
98%
Operating Margin
39%
Net Income Margin
30%
Return on Equity
0%
Return on Capital
1%
Return on Assets
51%
Earnings Yield
12.45%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$2.42B
Shares Outstanding
250.80M
Volume
263.77K
Short Interest
0.00%
Avg. Volume
5.28M
Financials (TTM)
Gross Profit
$855.76M
Operating Income
$340.99M
EBITDA
$347.65M
Operating Cash Flow
$329.88M
Capital Expenditure
$2.47M
Free Cash Flow
$327.41M
Cash & ST Invst.
$274.75M
Total Debt
$477.33M
BioCryst Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$406.56M
+209.1%
Gross Profit
$396.64M
+216.3%
Gross Margin
97.56%
N/A
Market Cap
$2.42B
N/A
Market Cap/Employee
$4.18M
N/A
Employees
580
N/A
Net Income
$245.84M
+1017.5%
EBITDA
$266.20M
+21689.3%
Quarterly Fundamentals
Net Cash
$202.58M
+61.1%
Accounts Receivable
$106.82M
+35.1%
Inventory
$5.40M
-33.3%
Long Term Debt
$437.25M
-45.7%
Short Term Debt
$40.08M
+13.1%
Return on Assets
51.32%
N/A
Return on Invested Capital
1.07%
N/A
Free Cash Flow
$275.23M
+4774.5%
Operating Cash Flow
$276.04M
+5395.1%